Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE-AF: OMT-28 for maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation
2018-001626-26Phase 2Completed
- Sponsor
- OMEICOS Therapeutics
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OMT-28 in Atrial fibrillation (AFib) (4 arms), sponsored by OMEICOS Therapeutics. Primary endpoint: Primary efficacy endpoints. Started Oct 2018; status: completed.
02
Drugs
OMT-28
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2018-001626-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001626-26.